Kura Oncology Inc. has presented its latest developments at the ASCO Investor Presentation, focusing on its investigational therapy for Acute Myeloid Leukemia $(AML.AU)$. The presentation highlighted the significant unmet needs in AML treatment, with approximately 22,010 new cases diagnosed annually in the United States and a 5-year survival rate of 33%. Kura Oncology's investigational drug, Ziftomenib, is a targeted menin inhibitor for relapsed/refractory and newly-diagnosed AML. The New Drug Application for Ziftomenib is based on positive results from the Phase 2 KOMET-001 trial and has been granted Priority Review with a Prescription Drug User Fee Act target action date set for November 30, 2025. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.